Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Durhalieve
- Development stage
- Discontinued
- Lead developer
- Echo Therapeutics
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
Durhalieve is a topical corticosteroid formulation developed by Echo Therapeutics for the treatment of corticosteroid-responsive dermatoses. The product was a 1% hydrocortisone cream designed using a proprietary transdermal drug delivery technology intended to enhance skin penetration and efficacy. Echo Therapeutics submitted a New Drug Application (NDA) for Durhalieve to the FDA in late 2006. However, following a merger with Sontra Medical in 2007, the company shifted its strategic focus toward its needle-free continuous glucose monitoring (CGM) system (Symphony) and its skin preparation system (Prelude), leading to the discontinuation of the Durhalieve program before it reached the market.
- Brand names
- Durhalieve
- Other names
- hydrocortisone 1% topical
02
Targets
GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on Durhalieve.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Durhalieve.